Prediagnostic Prostate-Specific Antigen Velocity and Probability of Detecting High-Grade Prostate Cancer

Urology

Volumn 69, Issue 3, 2007, Pages 515-519

  Krejcarek, Stephanie C ^a   Chen, Ming Hui ^b   Renshaw, Andrew A ^a   Loffredo, Marian ^a   Sussman, Brenda ^a   D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; UNIVARIATE ANALYSIS;

AGED; BIOPSY; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 33947213900     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.11.009     Document Type: Article

References (29)

1. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
2. Kupelian P.A., Elshaikh M., Reddy C.A., et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 20 (2002) 3376-3385
3. Grossfeld G.D., Latini D.M., Lubeck D.P., et al. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology 59 (2002) 560-565
4. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96-01 randomised controlled trial. Lancet Oncol 6 (2005) 841-850
5. D'Amico A.V., Manola J., Loffredo M., et al. 6-Month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 (2004) 821-827
6. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
7. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
8. D'Amico A.V., Renshaw A.A., Arsenault L., et al. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy. Int J Radiat Oncol Biol Phys 45 (1999) 841-846
9. Grossfeld G.D., Chang J.J., Broering J.M., et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 165 (2001) 851-856
10. King C.R., McNeal J.E., Gill H., et al. Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade. Urology 67 (2006) 1229-1234
11. D'Amico A.V., Chen M.H., Roehl K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
12. D'Amico A.V., Renshaw A.A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
13. Greene F.L., and American Joint Committee on Cancer and American Cancer Society. A JCC Cancer Staging Manual (2002), Springer-Verlag, New York
14. Klein J.P., and Moeschberger M.L. Survival Analysis: Techniques for Censored and Truncated Data. (1997), Springer, New York
15. Agresti A. Categorical Data Analysis. (2002), Wiley-Interscience, New York 165-210
16. Akaike H: Information and an extension of the maximum likelihood principle, in Petrov BN and Caski F (Eds): International Symposium on Information Theory. Budapest, Akademia Kiado, p 267-281.
17. Bostwick D.G. Gleason grading of prostatic needle biopsies: correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 18 (1994) 796-803
18. Gilliland F.D., Hoffman R.M., Hamilton A., et al. Predicting extracapsular extension of prostate cancer in men treated with radical prostatectomy: results from the population based prostate cancer outcomes study. J Urol 162 (1999) 1341-1345
19. Cookson M.S., Fleshner N.E., Soloway S.M., et al. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol 157 (1997) 559-562
20. Pinthus J.H., Witkos M., Fleshner N.E., et al. Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol 176 (2006) 979-984
21. King C.R. Patterns of prostate cancer biopsy grading: trends and clinical implications. Int J Cancer 90 (2000) 305-311
22. Mian B.M., Lehr D.J., Moore C.K., et al. Role of prostate biopsy schemes in accurate prediction of Gleason scores. Urology 67 (2006) 379-383
23. Lee A.K., Schultz D., Renshaw A.A., et al. Optimizing patient selection for prostate monotherapy. Int J Radiat Oncol Biol Phys 49 (2001) 673-677
24. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
25. D'Amico A.V., Hui-Chen M., Renshaw A.A., et al. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol 176 (2006) S11-S15
26. Tchetgen M.B., and Oesterling J.E. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 24 (1997) 283-291
27. Rafferty B., Rigsby P., Rose M., et al. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin Chem 46 (2000) 1310-1317
28. Chan T.Y., Chan D.Y., Stutzman K.L., et al. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?. J Urol 166 (2001) 2181-2184
29. Vira M.A., Tomaszewski J.E., Hwang W.T., et al. Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients. Urology 66 (2005) 1015-1019